Table 4.

Latency analyses for associations between TNFi exposure and selected cancers

Cancer site	Cases		Controls		aOR	95%CI		p trend
	N	%	N	%
NHL
Never exposed	607	77.5	25,544	83.8	-	-	-
Ever exposed	176	22.5	4,931	16.2	1.49	1.24	1.79
Exposure according to earliest claim								0.53
0–1 year prior	20	2.6	555	1.8	1.54	0.97	2.44
1–2 year prior	27	3.5	776	2.6	1.51	1.01	2.26
2–5 years prior	75	9.6	1892	6.2	1.71	1.33	2.21
5+ years prior	54	6.9	1708	5.6	1.32	0.98	1.78
Follicular lymphoma
Never exposed	61	66.3	25,544	83.8	-	-	-
Ever exposed	31	33.7	4,931	16.2	2.56	1.63	4.02
Exposure according to earliest claim								0.93
0–1 year prior	NR	NR	555	1.8	1.58	0.39	6.37
1–2 year prior	NR	NR	776	2.6	4.34	1.94	9.71
2–5 years prior	NR	NR	1892	6.2	2.19	1.09	4.38
5+ years prior	NR	NR	1708	5.6	2.62	1.36	5.06
NMSC
Never exposed	396	78.9	19,541	86.3	-	-	-
Ever exposed	106	21.1	3,905	16.7	1.43	1.16	1.77
Exposure according to earliest claim								0.08
0–1 year prior	21	4.2	424	1.8	2.19	1.38	3.48
1–2 year prior	21	4.2	590	2.5	1.90	1.19	3.01
2–5 years prior	29	5.8	1,489	6.4	1.02	0.70	1.50
5+ years prior	35	7.0	1,402	6.0	1.40	0.99	1.97

Abbreviations: aOR, adjusted odds ratio; TNFi, tumor necrosis factor inhibitor; NHL, non-Hodgkin lymphoma; NMSC, non-melanoma skin cancer; NR: not reported because cell size < 12

aOR: Odds ratio is adjusted for selection year, age, and race and sex where appropriate. Analyses for NMSC were restricted to White Medicare beneficiaries